

Supplemental online content for:

NCCN Guidelines as Model of Extended Criteria for Lung Cancer Screening

*Brady J. McKee, MD; Shawn Regis, PhD; Andrea K. Borondy-Kitts, MS, MPH;
Jeffrey A. Hashim, MD; Robert J. French Jr, MD; Christoph Wald, MD, MBA, PhD;
and Andrea B. McKee, MD*

J Natl Compr Canc Netw 2018;16(4):444–449

eTable 1: Staging Breakdown

eTable 2: Histology Breakdown

eTable 3: Vital Status

eTable 1. Staging Breakdown					
Cancer Type	Stage	Total	Group 1	Group 2	P Value
NSCLC ^a	0	3 (2.9%)	2 (2.6%)	1 (3.7%)	.83
	I	76 (73.8%)	54 (71.1%)	22 (81.5%)	.69
	II	7 (6.8%)	5 (6.6%)	2 (7.4%)	.73
	III	10 (9.7%)	10 (13.2%)	0 (0%)	.06
	IV	7 (6.8%)	5 (6.6%)	2 (7.4%)	.73
	Early-stage (≤II)	86 (83.5%)	61 (80.3%)	25 (92.6%)	.66
	Late-stage (III, IV)	17 (16.5%)	15 (19.7%)	2 (7.4%)	.21
	All stages	103 (91.1%)	76 (89.4%)	27 (96.4%)	.81
SCLC	Limited	5 (4.4%)	5 (5.9%)	0 (0%)	.25
	Extensive	2 (1.8%)	2 (2.4%)	0 (0%)	.57
	All stages	7 (6.2%)	7 (8.2%)	0 (0%)	.15
Unknown	NA	3 (2.7%)	2 (2.4%)	1 (3.6%)	.85

Abbreviations: NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.

^aPresumed lung cancer cases categorized as NSCLC.

eTable 2. Histology Breakdown				
Histology	Total	Group 1	Group 2	P Value
Adenocarcinoma	61 (54.0%)	42 (49.4%)	19 (67.9%)	.37
Squamous	23 (20.4%)	19 (22.4%)	4 (14.3%)	.45
Adenosquamous	1 (0.9%)	0 (0%)	1 (3.6%)	.25
Carcinoid	2 (1.8%)	2 (2.4%)	0 (0%)	.57
Small cell	7 (6.2%)	7 (8.2%)	0 (0%)	.15
Presumed lung cancer ^a	16 (14.2%)	12 (14.1%)	4 (14.3%)	.24
Unknown	3 (2.7%)	3 (3.5%)	0 (0%)	.43

^aBased on PET positivity, growth rate, and/or multidisciplinary consensus.

eTable 3. Vital Status				
Vital Status	Total	Group 1	Group 2	P Value
No evidence of disease	71 (62.8%)	49 (57.6%)	22 (78.6%)	.36
Alive with disease	18 (15.9%)	17 (20.0%)	1 (3.6%)	.05
Died of disease	10 (8.8%)	8 (9.4%)	2 (7.1%)	.30
Died of other cause	11 (9.7%)	8 (9.4%)	3 (10.7%)	.27
Died of unknown cause	2 (1.8%)	2 (2.4%)	0 (0%)	.57
Unknown	1 (0.9%)	1 (1.2%)	0 (0%)	.75